Share with your CIO
Salesforce is betting its next growth chapter on Agentforce, claiming $800 million in annual recurring revenue and 29,000 deals since launch against a backdrop of slowing top-line growth (fiscal 2026 revenue hit $41.5 billion, up just 10 percent versus 25 percent four years prior). But a Bloomberg report on University of Chicago Medicine reveals that several promoted Agentforce patient-facing capabilities, including AI-assisted prescription refills and appointment scheduling, remain unavailable to most patients due to product glitches and compliance approval delays. Signed deals and live production deployments are not the same number.
What this means for your business
The gap between a signed Agentforce contract and a working agent in production is the most important variable your renewal cycle doesn’t yet price in. If your organization is in a regulated industry, healthcare, financial services, insurance, the University of Chicago Medicine story is your story. Compliance review cycles, EHR integrations, and accountability questions about what happens when an agent acts on incomplete data don’t appear in a vendor demo, but they will appear in your implementation timeline. Where you sit depends on one question: has your team separated pilot metrics from production metrics yet?
The recurring failure mode here is what you might call demo-to-deployment drag, the period between a convincing proof of concept and the moment ordinary users actually touch the system. Salesforce’s own EVP acknowledged customers typically start simpler before scaling complexity, which is a tactful way of confirming the drag is real and expected. The risk for CIOs isn’t that Agentforce doesn’t work. It’s that the platform’s marketing clock and your organization’s operational clock are running at different speeds, and the gap is where budget pressure accumulates without delivered value.
The University of Chicago Medicine case will serve as a leading indicator for the entire category. If patient-facing scheduling and refill features ship broadly within the next twelve months, it validates the argument that complex regulated deployments simply take longer. If the scope quietly narrows or the timeline drifts again, every AI-native startup focused on a single workflow, prior authorization, benefits verification, discharge follow-up, gains a sharper pitch than any broad platform can answer. The renewal you should be weighing differently isn’t your Salesforce contract. It’s whether your pilot success criteria were written against demo conditions or production ones.
Based on reporting from Salesforce Agentforce faces reality check at scale, originally published 2026-05-22 03:00:00.
